NCT00546143View on ClinicalTrials.gov

Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

PHASE4CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2008

Conditions

Asthma

Interventions

DRUG

Omalizumab

DRUG

Omalizumab

DRUG

Omalizumab

Trial Locations (5)

Unknown

Novartis Investigative Site, Berlin

Novartis Investigative site, Hamburg

Novartis investigative site, Hanover

Novartis investigative site, Mainz

Novartis Investigative site, Bloemfontein

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY

NCT00546143 - Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma | Biotech Hunter | Biotech Hunter